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TuberculosisA B S T R A C T
.Introduction
Multidrug-resistant (MDR)/extensively drug-resistant (XDR)
tuberculosis (TB) is a significant threat to global TB control
[1]. In most cases, treatment of MDR/XDR TB is not standard-
ized, and clinicians have adopted a variety of treatment
strategies. These strategies include switching to a regimen
of new drugs, increasing the dosage of the same drugs, rarely
used drugs (which have widespread resistance), etc. Drug
resistance is a manmade phenomenon that is driven by treat-
ment strategy (i.e., regimen). These divergent approaches
may differentially drive the evolution of bacteria. Some
instances of this evolution have already occurred [2]. The
community’s focus has been on drug resistance; therefore,the consequence of this divergence is usually by different
mechanisms of resistance [2,3]. However, the full scope of
the consequential microevolution frequently goes unnoticed
because it also affects important factors such as fitness and
virulence. In this study, we aimed to develop a comprehensive
understanding of the consequences of differential TB treat-
ment to build more accurate prognostics for future
treatments.
Methods
We studied 385 (mostly XDR) clinical Mycobacterium tuberculo-
sis isolates from five countries: India, the Philippines, Mol-
dova, South Africa, and Sweden. Whole genome sequencingrminant of
2 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y x x x ( 2 0 1 6 ) x x x –x x xwas performed on Pacific Biosciences (1380 Willow Road,
Menlo Pak, CA 94025, USA) RS I and II platforms. Drug suscep-
tibility testing for eight first- and second-line drugs was per-
formed on mycobacteria growth indicator tubes (MGIT)
(MGIT960; Bactec, Becton, Dickinson and Company, 1 Becton
Drive, Franklin Lakes, New Jersey 07417-1880, USA) for all iso-
lates. Each isolate’s mechanisms of resistance to each drug
was identified andmapped to the geographic origin of the iso-
late. Genome-wide phylogenomics was used for ancestral
reconstruction. Clonality was studied to identify outbreaks
and used as a proxy for measuring virulence. Growth curves
in MGITwere also studied for the estimation of fitness.
Results
Some mechanisms of resistance seem to be region-specific.
Several clonal expansions were identified among the MDR
and XDR isolates from India and South Africa. Growth curve
analysis identified two distinct processes. The first process
has a lower growth rate and subsides after a few days, but it
predominantly drives the growth in the initial days. The sec-
ond process has a distinctly higher growth rate and begins a
few days later (or has an immeasurable growth rate in the first
few days) and drives all or most of the growth after the first
few days of incubation. We observed isolates that seemed to
start their second phase very late or not at all.
Discussion
Specificity of a mechanism of resistance to a region is a great
concern and a phenomenon that is not well understood.
However, it is a clear indication of the multiplicity of an evo-
lutionary path to a phenotypic resistance state. The evolu-
tionary past is a determinant of the evolutionary trajectory;
therefore, the concern is that bacteria will continue to evolve
differentially in different regions of the world and hence will
require different treatment strategies. In such a scenario, a
standard global treatment of TB will have to be abandoned.Please cite this article in press as: F Valafar. Pathogenesis of multi drug-re
future treatment success. Int. J. Mycobacteriol. (2016), http://dx.doi.org/1The missing (or delayed) secondary growth process is also
of grave concern because it allows the bacterium to escape
growth-based phenotypic detection. This is the World Health
Organization’s recommendation, andmost prevalent method,
for determining resistance; therefore, this escape undoubt-
edly is a path to achieving an MDR/XDR state and undermines
global TB control. Such resistant isolates would be labeled as
‘‘susceptible” and standard treatment would continue, and
thereby provide time for the development of additional resis-
tance. The clonal expansion of MDR/XDR bacteria clearly dis-
pels the notion that highly resistant isolates are less fit or
virulent. This factor may be true for some bacteria; however,
we also foundmuch contradicting evidence. This finding indi-
cates differential microevolution and results in differential
fitness and virulence.
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